Genethon and Ampersand Target a New Era of Safer Gene Therapies

ÉVRY, France and BOSTON – May 21, 2026 – French gene therapy pioneer Genethon and the AI-driven Ampersand Biomedicines have announced an exclusive collaboration to engineer a new generation of gene therapy delivery vehicles, a move that aims to solve one of the most persistent challenges in modern medicine: precision. The partnership seeks to create adeno-associated virus (AAV) vectors that can home in on specific tissues, promising safer, more effective treatments for rare genetic diseases.

The collaboration unites Genethon, a non-profit laboratory with a storied history in developing therapies for rare diseases, and Ampersand, a venture-backed firm using artificial intelligence to design smarter medicines. By combining their distinct expertise, they hope to unlock the full potential of AAV-based gene therapy, moving beyond current limitations that have hampered the field.

The High Stakes of Gene Therapy Delivery

Gene therapy holds immense promise, offering the potential to correct genetic defects at their source. The most common delivery tool is the adeno-associated virus, a non-pathogenic virus repurposed to carry therapeutic genetic payloads into human cells. Despite its success, the technology faces a critical hurdle: a lack of precision.

Naturally occurring AAVs have a strong affinity for the liver. When administered systemically, a large portion of the vector dose accumulates in this organ, regardless of the intended target. To ensure enough of the therapy reaches tissues like muscle or the central nervous system, clinicians must administer extremely high doses. This brute-force approach comes with significant risks and costs.

High vector doses can trigger severe immune responses and lead to "on-target, off-tissue" toxicity, where the therapy affects healthy cells. Hepatotoxicity, or liver damage, is a well-documented concern. In some high-profile clinical trials, severe adverse events, including fatalities, have been linked to the massive viral loads required. Furthermore, the human immune system is adept at recognizing and neutralizing these vectors. Many potential patients are ineligible for treatment due to pre-existing antibodies from natural AAV exposure. For those who do receive a dose, the resulting immune memory makes re-administration of the same therapy virtually impossible.

These challenges have created a ceiling for gene therapy's potential, limiting its safety, efficacy, and patient population. The industry has been in a period of reset, with several major pharmaceutical companies scaling back AAV programs due to safety concerns and commercial hurdles, creating an urgent need for a technological leap forward.

A Two-Pronged Attack: AI Meets AAV Engineering

The Genethon-Ampersand partnership represents a direct assault on these limitations, tackling the problem from two complementary angles: AI-powered targeting and expert vector design.

Ampersand Biomedicines, a company founded by the venture creation firm Flagship Pioneering, brings its computationally powered Address, Navigate, Determine (AND)™ Platform to the table. At the heart of this platform is the "Address Map," a proprietary, AI-driven characterization of human biology that identifies unique molecular "addresses" on specific cell types across every major tissue. The platform's algorithms search this map to find exquisitely selective ligands—or "localizers"—that can guide a therapy directly to its intended destination and nowhere else.

This technology has already attracted significant attention and capital, including a strategic partnership with Pfizer for obesity-related targets and investment from pharmaceutical giant Eli Lilly, lending external validation to its novel approach.

"At Ampersand, we aim to address one of medicine's central challenges: delivering therapies exactly where they are needed," said Jason Gardner, D.Phil., Chief Executive Officer of Ampersand Biomedicines. "By combining our unique targeting capabilities with Genethon's expertise in AAV engineering, we are looking forward to contributing to the next generation of safer and more efficacious therapies."

Genethon provides the other half of the equation. As a non-profit laboratory created by the French Muscular Dystrophy Association (AFM-Téléthon), Genethon has been a central figure in gene therapy for decades. It contributed to the development of the first approved gene therapy for spinal muscular atrophy (SMA) and currently has over a dozen products in clinical trials for a range of devastating rare diseases. Under the new collaboration, Genethon’s scientists will leverage this deep expertise to integrate the tissue-specific localizers identified by Ampersand onto the surface of AAV capsids, effectively creating a biological guidance system for the therapeutic payload.

"Precision targeting is a key driver for improving both the efficacy and tolerability of gene therapy," emphasized Frédéric Revah PhD., Chief Executive Officer of Genethon. "By directing the vector exclusively to the tissues of interest, higher potency with lower doses can be used, systemic exposure is reduced, and immune responses can be minimized."

A New Horizon in a Crowded Field

The collaboration's initial focus will be on skeletal muscle, a key battleground for genetic diseases like Duchenne muscular dystrophy and a core area of Genethon's expertise. Success here could pave the way for expansion into a broad range of other tissues and organs. For patients and their families, the prospect of more targeted therapies means a new level of hope. A treatment that requires a lower dose is inherently safer, less likely to cause debilitating side effects, and potentially more accessible from a manufacturing and cost perspective.

This partnership enters a highly competitive landscape. Companies like 4D Molecular Therapeutics, Dyno Therapeutics, and Voyager Therapeutics are also racing to develop next-generation AAVs with enhanced targeting capabilities, many using their own proprietary capsid engineering and AI-driven platforms. The field is crowded with innovation, underscoring the universal recognition that better delivery vectors are the key to unlocking gene therapy's future.

What sets the Genethon-Ampersand alliance apart is its unique structure. It pairs a mission-driven, non-profit research powerhouse with a hyper-focused, AI-native biotech born from Flagship Pioneering's venture creation model. This blend of deep-seated patient advocacy and cutting-edge computational biology could create a powerful synergy.

By directly addressing the core issues of safety and specificity, this collaboration aims not just to create a better product, but to fundamentally change the risk-benefit calculus for gene therapies. If successful, their work could produce vectors that are not only more effective but also safer for a wider range of patients, potentially transforming the standard of care for numerous rare genetic disorders.